Medii and Asahi Kasei Therapeutics Collaborate to Optimize Early Diagnosis and Treatment of DIC

Medii, Inc. and Asahi Kasei Therapeutics Co., Ltd. announced that they will begin a collaborative effort on June 1 to promote early diagnosis and optimal treatment of Disseminated Intravascular Coagulation (DIC).

In this initiative, the companies will jointly conduct awareness activities, including the promotion of a case consultation window staffed by experts well-versed in DIC within Medii's specialized physician consultation service, 'Medii E-Consult,' and the distribution of DIC-related clinical content. This initiative aims to provide physicians nationwide with rapid access to expert knowledge, contributing to improved quality of care and treatment optimization in DIC.

Background DIC is a life-threatening condition where the balance between blood clotting and dissolution is lost, potentially leading to multi-organ failure and massive hemorrhage. Triggered by underlying conditions such as infections, cancer, trauma, or obstetric complications, its causes and progression vary widely per patient. Consequently, treatment plans are not uniform and must be adjusted to dynamically changing conditions, making it one of the most challenging areas of medical practice.

Recognizing these challenges, the collaboration was established between Asahi Kasei Therapeutics, which has been involved in disease awareness, and Medii, which supports knowledge sharing among physicians.

By creating an environment where primary physicians can discuss cases with expert specialists online, this collaboration enables decision-making support regardless of regional or institutional infrastructure.

DIC Case Consultation Window URL: https://x.medii.jp/8c4eab *Note: Medii E-Consult is intended for information sharing between physicians and is not a medical device. This service is for physicians only, and free membership registration is required.

Neutrality and Independence Responses to consultations are based on the independent medical perspective of each expert specialist and are not influenced by Medii or Asahi Kasei Therapeutics.